Overview
- Oral Wegovy, the first GLP-1 weight-loss pill, launched in the U.S. and recorded 18,410 prescriptions in its first full week.
- Novo Nordisk shares were up about 26% for the year through Jan. 26, outpacing the broader market.
- BMO raised its Novo Nordisk price target to $57 from $47 but kept a Market Perform rating.
- The firm cut its 2025 Wegovy sales estimate to DKK 77.8 billion and projects roughly flat 2026 U.S. prescription volumes, implying negative year-over-year U.S. net sales.
- BMO cited pricing pressure and recent flat TRx trends, noting a CVS exclusivity agreement as a tailwind, after Novo Nordisk lowered 2025 sales-growth guidance last year due to competition and compounding knock-offs.